Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | May 20, 2026 | May 23, 2026 |
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 15, 2021 | June 17, 2021 |
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 14, 2026 | May 18, 2026 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | January 06, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date May 20, 2026 · Filed May 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 18,222 |
Ending reported balance
After 2026-05-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-21 · Exercise / conversion · Acquired 6,142 · Balance 19,697 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-05-21 · Tax withholding · Disposed 1,475 · Balance 18,222 |
| Non Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.98 · Expires 2036-05-20 | Direct | 11,538 |
Reported balance
After 2026-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-20 · Grant · Acquired 11,538 · Balance 11,538 F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 5,409 |
Reported balance
After 2026-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-20 · Grant · Acquired 5,409 · Balance 5,409 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-21 · Exercise / conversion · Disposed 6,142 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant.
F3: This award is fully vested in accordance with its terms.
Aquestive Therapeutics, Inc.
Report date June 15, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2031-06-15 | Direct | 20,000 |
Reported balance
After 2021-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Ms. Lurker's continuous service with the Issuer from the grant date through the applicable vesting date.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,758 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 8,741 · Balance 26,758 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
EyePoint, Inc.
Report date January 06, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 294,346 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Exercise / conversion · Acquired 75,133 · Balance 294,346 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-01-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-06 · Exercise / conversion · Disposed 75,133 · Balance 0 F2: The restricted stock units vest in three ratable annual installments beginning January 6, 2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 126,889 |
Reported balance
Holding disclosure · report date 2026-01-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 126,889 F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2: The restricted stock units vest in three ratable annual installments beginning January 6, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2024 Filed Aug 20, 2024 20:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | PurchaseCommon Stock | 3,173 | $7.88 | $25,003.24 |
DisclosureSEC source: 0001562180-24-006378 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,635 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $7.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 10 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 16,666 Underlying: Common Stock · 16,666 shares Expires 2033-07-10 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 9 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 16,666 shares Expires 2033-07-10 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 56,350 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 8 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 169,050 Underlying: Common Stock · 56,350 shares Expires 2033-01-05 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 56,350 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 7 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,750 Underlying: Common Stock · 56,350 shares Expires 2033-01-05 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 145,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-09 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-09 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 26,713 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 182,535 Underlying: Common Stock · 26,713 shares Expires 2031-02-09 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 26,713 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,165 Underlying: Common Stock · 26,713 shares Expires 2031-02-09 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 1,558 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 74,800 Underlying: Common Stock · 1,558 shares Expires 2030-02-28 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 26, 2024 Filed Jul 26, 2024 20:47 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 1,558 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,558 shares Expires 2030-02-28 F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust"). F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 21:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 11,111 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005700 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,223 Underlying: Common Stock · 11,111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 21:03 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 11,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005700 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:56 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,492 | $0.00 Strike: $23.40 | $0.00 |
DisclosureSEC source: 0001127602-24-017727 · form4.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 20:56 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017727 · form4.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 20:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 22,103 | $0.00 Strike: $24.99 | $0.00 |
DisclosureSEC source: 0001127602-24-012829 · form4.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,103 Underlying: Ordinary Shares · 22,103 shares Expires 2034-04-11 F5 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 4/11/2025. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 20:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 11,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012829 · form4.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,255 Underlying: Ordinary Shares · 11,255 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 4/11/2025. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 4/11/2025. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 20:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 4,833 | $0.00 Strike: $24.99 | $0.00 |
DisclosureSEC source: 0001127602-24-012829 · form4.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,833 Underlying: Ordinary Shares · 4,833 shares Expires 2034-04-11 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 4/11/2025. Read SEC document |
| April 11, 2024 Filed Apr 12, 2024 20:16 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 2,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-012829 · form4.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,323 Underlying: Ordinary Shares · 2,323 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 4/11/2025. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 4/11/2025. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 14 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 115,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 13 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 5,000 shares Expires 2032-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 4,452 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 12 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 155,822 Underlying: Common Stock · 4,452 shares Expires 2031-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F8 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 4,452 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 11 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,878 Underlying: Common Stock · 4,452 shares Expires 2031-02-09 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F8 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 9, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 3,116 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 10 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 73,242 Underlying: Common Stock · 3,116 shares Expires 2030-02-28 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 28, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 3,116 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 9 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,558 Underlying: Common Stock · 3,116 shares Expires 2030-02-28 F6 · kind: On February 13, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of January 28, 2024. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftCommon Stock | 74,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 6 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 126,889 F2 · kind: On February 13, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 13, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftCommon Stock | 74,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 5 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,351 F2 · kind: On February 13, 2024, the reporting person transferred owned shares of Common Stock of the Company to the Family Trust. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 8 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 17,534 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · derivative · entry 7 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,534 shares Expires 2031-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 6,981 | $28.80 | $201,052.80 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 4 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,032 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 7,962 | $28.80 | $229,305.60 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 3 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,013 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 17,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:40 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001294 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 112,700 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-000636 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: Plan reported Ownership: Indirect · By Family Trust Disclosed balance after: 112,700 Underlying: Common Stock · 112,700 shares Expires 2033-01-05 F4 · kind: On January 24, 2024, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on January 6, 2023 and was exercisable for 112,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 112,700 shares of Common Stock of the Company. F5 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 112,700 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-24-000636 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 338,100 Underlying: Common Stock · 112,700 shares Expires 2033-01-05 F4 · kind: On January 24, 2024, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on January 6, 2023 and was exercisable for 112,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 112,700 shares of Common Stock of the Company. F5 · derivative.exercise_date: The option to purchase vests and becomes exercisable as follows: 25% at January 6th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 24, 2024 Filed Jan 25, 2024 23:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 29,956 | $24.98 | $748,249.95 |
DisclosureSEC source: 0001562180-24-000636 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,441 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.24. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 23:24 UTC | EyePoint, Inc. EYPT · Entity 5702 | SaleCommon Stock | 5,044 | $24.97 | $125,949.69 |
DisclosureSEC source: 0001562180-24-000636 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,397 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.95 to $25.00. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:17 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 75,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,267 Underlying: Common Stock · 75,133 shares Expires 2033-06-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning January 6, 2024. Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:17 UTC | EyePoint, Inc. EYPT · Entity 5702 | Tax withholdingCommon Stock | 23,043 | $20.40 | $470,077.20 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · nonDerivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,441 F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units Read SEC document |
| January 06, 2024 Filed Jan 10, 2024 02:17 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 75,133 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · nonDerivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:17 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 77,000 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2034-01-04 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 02:17 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 38,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000402 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-01-05 F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 6 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 110,000 Underlying: Common Stock · 35,000 shares Expires 2032-02-09 F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023. F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 5 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 35,000 shares Expires 2032-02-09 F6 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023. F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 10,906 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 4 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 70,126 Underlying: Common Stock · 10,906 shares Expires 2030-02-28 F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023. F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 10,906 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 3 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,674 Underlying: Common Stock · 10,906 shares Expires 2030-02-28 F4 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on February 28, 2020 and was exercisable for 74,800 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 71,684 shares of Common Stock of the Company, of which 59,220 had been previously gifted on May 11, 2023. F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of April 28, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 28, 2024. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 31,164 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 2 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 151,370 Underlying: Common Stock · 31,164 shares Expires 2031-02-09 F1 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 28, 2023 Filed Jan 2, 2024 22:41 UTC | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 31,164 | $0.00 Strike: $13.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000035 · primarydocument.xml · derivative · entry 1 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,330 Underlying: Common Stock · 31,164 shares Expires 2031-02-09 F1 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2021 and was exercisable for 213,700 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 151,370 shares of Common Stock of the Company, of which 120,206 had been previously gifted on May 11, 2023. F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025. Read SEC document |
| December 28, 2023 Filed Jan 3, 2024 23:37 UTC Amendment | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 8 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 110,000 Underlying: Common Stock · 35,000 shares Expires 2032-02-09 F8 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023. F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| December 28, 2023 Filed Jan 3, 2024 23:37 UTC Amendment | EyePoint, Inc. EYPT · Entity 5702 | GiftStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $10.13 | $0.00 |
DisclosureSEC source: 0001562180-24-000133 · primarydocument.xml · derivative · entry 7 Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 35,000 shares Expires 2032-02-09 F8 · kind: On December 28, 2023, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on February 9, 2022 and was exercisable for 240,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 110,000 shares of Common Stock of the Company, of which 75,000 had been previously gifted on May 11, 2023. F9 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of December 9, 2023. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.